Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3722259 | 0.86 | ALDH1A1 (0.45) | ALDH1A1GAAMEN1KMT2AMAPT | |
| SCHEMBL28620316 | 0.80 | LMNA (0.41) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4774060 | 0.79 | MAPT (0.48) | ALDH1A1GAAMEN1KMT2AMAPT | |
| SCHEMBL3728081 | 0.78 | LMNA (0.54) | ALDH1A1GAAMEN1KMT2AMAPT | |
| SCHEMBL12388688 | 0.77 | FFAR1 (0.44) | ALDH1A1GAAMEN1KMT2AATM | |
| SCHEMBL8773593 | 0.77 | SLC6A4 (0.43) | ALDH1A1GAAMEN1KMT2AMAPT | |
| SCHEMBL1346422 | 0.76 | SLC6A4 (0.58) | ALDH1A1MEN1KMT2AMAPTSLC6A4 | |
| SCHEMBL2296988 | 0.76 | CA2 (0.47) | ALDH1A1MEN1KMT2AMAPTATM | |
| SCHEMBL29725217 | 0.76 | CA2 (0.47) | ALDH1A1MEN1KMT2AMAPTATM | |
| SCHEMBL3081718 | 0.75 | SLC6A4 (0.50) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2002837-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1094816-B1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-10 | — | — | EP | disclosed |
| EP-1741713-A2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | Bristol-Myers Squibb Company (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1237888-B1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2006-09-13 | — | — | EP | disclosed |
| US-6852745-B2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-08 | — | — | US | disclosed |
| US-6835741-B2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-28 | — | — | US | disclosed |
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-06-03 | — | — | US | disclosed |
| US-6638937-B2 | As antihypertensive agents; for therapy of disorders related to renal, glomerular and mesangial cell function; therapy of endotoxemia or endotoxin shock as well as hemorrhagic shock; useful in alleviation of pain associated cancer | BRISTOL-MYERS SQUIBB CO. | 2003-10-28 | — | — | US | disclosed |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2002-10-03 | — | — | US | disclosed |
| EP-1237888-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-1094816-A4 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2001044239-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-1094816-A1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000001389-A1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | ALDH1A1 1854/4885GAA 1248/4885MEN1 3697/4885 |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | ALDH1A1 1854/4885GAA 1248/4885MEN1 3697/4885 |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | ALDH1A1 1854/4885GAA 1248/4885MEN1 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.